Lebrikizumab-Lbkz

Introduction Overview

Generic Name

lebrikizumab-lbkz

Brand Name

Ebglyss

Dosage Form

Subcutaneous injection (250 mg/2 mL)

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption:
Lebrikizumab, administered subcutaneously as Ebglyss, demonstrates a pharmacokinetic profile consistent with monoclonal antibodies. Upon subcutaneous injection, absorption occurs via lymphatic uptake and subsequent entry into the systemic circulation. The bioavailability of lebrikizumab is high, reflecting efficient absorption from the subcutaneous tissue. Peak plasma concentrations are generally reached within days post-administration, accounting for its dosing schedule every two weeks initially, moving to monthly maintenance dosing. Factors influencing absorption include injection site blood flow and patient-specific variables such as body weight and subcutaneous fat thickness.

Distribution:
Following systemic absorption, lebrikizumab distributes primarily within the vascular and interstitial spaces, typical of large biologic molecules. It does not cross cell membranes readily due to its molecular size and is confined to extracellular compartments. Volumes of distribution approximate plasma volume, suggesting limited distribution beyond extracellular fluids. Binding to its target, interleukin-13 (IL-13), may affect distribution dynamics, particularly in tissues with elevated IL-13 expression, such as inflamed skin in atopic dermatitis. There is minimal penetration into the central nervous system.

Metabolism:
Lebrikizumab, like other monoclonal antibodies, undergoes catabolic metabolism through proteolytic degradation into small peptides and amino acids via reticuloendothelial system pathways. This process occurs mainly in lysosomes within phagocytic cells and other vascular endothelial cells. The metabolism is non-enzymatic and does not involve cytochrome P450 enzymes, minimizing potential drug-drug interactions mediated through hepatic metabolism. The metabolic rate correlates with factors such as target antigen levels and immunogenic responses.

Elimination:
Elimination of lebrikizumab occurs primarily through proteolytic catabolism, with minimal renal clearance due to its large molecular weight. The terminal half-life supports the dosing interval of biweekly administration initially with subsequent monthly maintenance dosing. Clearance can be influenced by target-mediated drug disposition, where binding to IL-13 may increase clearance, especially in patients with higher disease activity. Immunogenicity, including anti-drug antibody development, may also affect clearance and efficacy. No significant hepatic or renal elimination pathways have been reported, underscoring predictable pharmacokinetics in patients with organ impairment.

Dosage Forms

Available Dosage Forms:
Ebglyss is available as a subcutaneous injection delivered via prefilled pen and prefilled syringe. Each device contains 250 mg of lebrikizumab-lbkz in 2 mL of solution. The formulations ensure ease of administration with a needle shield to enhance safety and patient adherence.

Dosages for Adults and Adolescents:
The recommended induction dose is 500 mg, administered as two 250 mg injections subcutaneously at Week 0 and Week 2. Following induction, a maintenance dose of 250 mg is administered every two weeks until Week 16 or until an adequate clinical response is reached. Thereafter, the dosing interval shifts to once every four weeks for maintenance therapy. This regimen applies to adults and pediatric patients aged 12 years and older weighing at least 40 kg (approximately 88 pounds).

Specific Patient Populations:
Ebglyss is indicated for patients with moderate-to-severe atopic dermatitis who are inadequately controlled with topical prescription therapies. The dosing regimen remains consistent across approved patient populations, with adjustments guided by clinical response and tolerability. There are no current dose adjustments specified for renal or hepatic impairment given its metabolism and elimination pathways. Caution is advised in patients with pre-existing parasitic infections, and treatment of helminth infections should be completed prior to initiation. Pediatric use is approved down to 12 years of age with a minimum weight of 40 kg; safety and efficacy below this age or weight have not been established.

Mechanism Of Action

Ebglyss (lebrikizumab-lbkz) is a humanized monoclonal antibody designed to selectively bind to and inhibit interleukin-13 (IL-13), a cytokine pivotal in the pathophysiology of atopic dermatitis. IL-13 is a key mediator driving the inflammatory cascade in atopic skin lesions, contributing to symptoms such as skin barrier dysfunction, itch, and inflammatory cell recruitment.

At the molecular level, lebrikizumab binds with high affinity to IL-13, preventing its interaction with the IL-13 receptor α1 subunit on target cells. This blockade inhibits downstream signaling pathways, notably the Janus kinase (JAK)-signal transducer and activator of transcription 6 (STAT6) pathway. Inhibition of this pathway reduces the transcription of pro-inflammatory genes, including those responsible for inflammatory cell recruitment, IgE production, and other mediators that exacerbate atopic dermatitis.

Cellularly, this inhibition leads to diminished activation of keratinocytes, fibroblasts, and immune cells such as eosinophils and T-helper 2 (Th2) lymphocytes, resulting in reduced skin inflammation and restoration of skin barrier integrity. The blockade also alleviates neural sensitization implicated in the pruritus (itch) characteristic of atopic dermatitis.

Clinically, targeting IL-13 with Ebglyss has demonstrated significant improvements in skin clearance, itch relief, and quality of life in patients with moderate-to-severe atopic dermatitis who had inadequate response to topical therapies. This targeted mechanism differs from broad immunosuppressants by offering specificity, potentially reducing systemic side effects. Comparative studies position lebrikizumab alongside other IL-13 antagonists and IL-4/IL-13 inhibitors, with ongoing research to delineate comparative efficacy and safety profiles.

Pharmacological Actions

Selective inhibition of interleukin-13 (IL-13), a key cytokine in type 2 inflammation.
Reduction of skin inflammation by blockade of IL-13-mediated signaling pathways.
Improvement of epidermal barrier function through modulation of keratinocyte activity.
Alleviation of pruritus by reducing neural sensitization in atopic skin.
Diminution of immune cell recruitment, including eosinophils and Th2 cells, to the skin.
Suppression of IgE production and downstream allergic responses.
Modulation of cytokine networks involved in chronic atopic dermatitis pathogenesis.
Biologic agent with targeted immunomodulatory effects rather than broad immunosuppression.
Preservation of systemic immune competence due to selective cytokine targeting.
Therapeutic effects emerging within weeks of treatment initiation, with progressive improvement.
Used as monotherapy or in combination with topical corticosteroids or calcineurin inhibitors.

Therapeutic Or Clinical Uses

Treatment of moderate-to-severe atopic dermatitis (eczema) in patients aged 12 years and older.
Management of atopic dermatitis not adequately controlled with topical prescription therapies.
Reduction of skin lesions, inflammation, and symptoms associated with atopic dermatitis.
Alleviation of pruritus and improvement in patient quality of life.
Maintenance therapy to sustain disease control after initial response.
Adjunctive therapy alongside topical corticosteroids or immunomodulators in certain cases.
Suitable for long-term management due to targeted mechanism and safety profile.
Therapeutic option for patients who have contraindications or inadequate response to other systemic agents.
Potential off-label use in other IL-13 mediated inflammatory conditions under investigation.
Use in pediatric populations (≥12 years, ≥40 kg) for atopic dermatitis requiring systemic intervention.

Side Or Adverse Effects

Injection site pain or reactions including redness, swelling, and discomfort.
Herpes zoster (shingles) occurrences reported with treatment.
Eye and eyelid inflammation such as conjunctivitis characterized by redness, itching, and swelling.
Serious allergic reactions including anaphylaxis, marked by symptoms such as wheezing, facial swelling, hives, and dizziness.
Possible keratitis (corneal inflammation) manifesting as eye pain or visual changes.
Hypersensitivity reactions including angioedema and urticaria.
Potential exacerbation of pre-existing or development of new parasitic infections.
Rare systemic hypersensitivity reactions necessitating drug discontinuation.
Common side effects occurring at a rate ≥1% of treated patients.
Non-specific symptoms such as headache or fatigue have been reported anecdotally.
No significant hepatic or renal adverse effects observed given biologic pharmacology.
Long-term safety data continues to be collected to monitor for rare adverse events.
Patients should be monitored closely for any new onset or worsening eye symptoms.
Prompt medical evaluation recommended for signs of severe allergic or hypersensitivity reactions.

Precautions

Assess for and treat any pre-existing parasitic (helminth) infections prior to initiation.
Avoid use of live vaccines during treatment due to immunomodulatory effects.
Educate patients on recognizing signs of serious allergic reactions and eye inflammation.
Perform baseline and periodic evaluations of ocular health during therapy.
Use caution in patients with known hypersensitivity to lebrikizumab or formulation excipients.
Advise on proper subcutaneous injection technique and site rotation to minimize injection site reactions.
Consider potential immunosuppression-related infection risks and counsel accordingly.
Ensure appropriate patient selection, especially in adolescents weighing ≥40 kg.
Pregnancy effects are unknown; use only if benefit outweighs risk and consult healthcare provider if pregnant or planning pregnancy.
Lactation safety is not established; caution advised for breastfeeding mothers.
Monitor for symptom worsening which might indicate adverse reactions or infection.
Store medication under recommended conditions to maintain stability and efficacy.
Avoid injections into affected, tender, or compromised skin areas to reduce site reactions.
Notify healthcare providers of all concomitant medications to evaluate for interactions.

Warnings

Do not use if allergic to lebrikizumab-lbkz or any inactive ingredients in Ebglyss.
Risk of serious hypersensitivity reactions including anaphylaxis; discontinue drug if these occur.
Potential for conjunctivitis and keratitis; promptly report new or worsening eye symptoms.
Possible exacerbation or new onset of parasitic infections; ensure treatment of helminth infections before starting therapy.
Avoid live vaccines during treatment to prevent vaccine-related adverse events.
Increased susceptibility to infections due to immunomodulation.
In rare cases, serious allergic reactions may manifest as swelling of the face, lips, mouth, tongue or throat.
Monitor closely during initial dosing phases when adverse reactions are more likely.
Use caution in patients with underlying immunodeficiency or ongoing infections.
Discontinue immediately upon signs of serious allergic reactions or intolerable adverse events.
Risk-benefit should be carefully assessed in pregnant or breastfeeding individuals due to lack of safety data.
Store medication properly to avoid degradation and potential safety issues.
Educate patients to seek immediate medical attention if severe allergic symptoms arise.
Not recommended in patients with active or untreated helminth infections.

Contraindication

Known hypersensitivity or allergy to lebrikizumab-lbkz or any formulation excipients.
Active untreated helminth (parasitic worm) infection.
Previous severe hypersensitivity reaction to this drug or similar IL-13 inhibitors.
Use of live vaccines concomitantly or within a period of immunosuppressive effect.
Patients with a history of severe allergic or anaphylactic reactions to monoclonal antibody therapies may require an alternative treatment.
Individuals with active serious infections until resolution.
Contraindicated in patients who have demonstrated intolerance or serious adverse reactions to Ebglyss in the past.
Not approved for use in patients younger than 12 years of age or under 40 kg body weight due to lack of safety and efficacy data.
Patients with ocular inflammatory conditions without caution or monitoring.
Patients with uncontrolled immune system disorders without specialist evaluation.

Drug Interactions

No direct cytochrome P450 mediated drug interactions due to monoclonal antibody metabolism.
Potential interaction with live vaccines leading to serious infection; live vaccines should be avoided during treatment.
Concomitant use with other immunosuppressive biologics may increase risk of infection or adverse immune effects.
No significant interactions reported with common topical corticosteroids or calcineurin inhibitors used concurrently.
Co-administration with drugs affecting immune function requires close monitoring for increased infection risk.
Herbal or over-the-counter immunomodulatory supplements have unknown interaction potential and should be disclosed to healthcare providers.
No known pharmacokinetic interactions that alter lebrikizumab’s absorption, distribution, metabolism, or elimination.
Drugs that induce or inhibit proteolytic catabolism pathways are unlikely to affect lebrikizumab clearance significantly.
Potential for additive risk when combined with systemic corticosteroids not fully evaluated.
Vaccination timing must be planned carefully to avoid immunization failure or safety concerns.
Drug interaction profiles remain under post-marketing surveillance due to novel therapeutic class.
Inform prescribing clinicians of all current medications for thorough interaction assessment.

Preparations Of The Drug

Ebglyss comes as a 250 mg dose in a 2 mL single-use prefilled pen for subcutaneous injection.
Also available as a 250 mg dose in a 2 mL single-use prefilled syringe with a needle shield.
Formulated as a clear to opalescent, colorless to slightly yellow to slightly brown sterile solution.
Inactive ingredients include glacial acetic acid, histidine, polysorbate 20, sucrose, and Water for Injection with pH adjusted between 5.4 and 6.0.
Products are supplied with detailed Instructions for Use illustrating proper preparation and administration steps.
The medication is supplied refrigerated and should be protected from light and excessive heat.
Each device is designed for ease of use, with patients or caregivers trained to self-administer injections.
Prefilled devices eliminate need for reconstitution, minimizing dosing errors and contamination risk.
Not made with natural rubber to reduce risk of latex allergy reactions.
Storage instructions include refrigeration between 2°C and 8°C (36°F to 46°F) until use.
If necessary, Ebglyss devices can be kept at room temperature (up to 30°C) for a single period not exceeding seven days.
Unused or compromised doses must be discarded according to recommended waste protocols.
Proper training is essential to avoid injection site complications and ensure full dose delivery.